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The human glucose transporter protein 1 (GLUT-1) functions as a receptor for human T cell leukemia virus (HTLV). GLUT-1 is a twelve-
transmembrane cell surface receptor with six extracellular (ECL) and seven intracellular domains. To analyze HTLV-1 cytotropism, we utilized
polyclonal antibodies to a synthetic peptide corresponding to the large extracellular domain of GLUT-1. The antibodies caused significant
blocking of envelope (Env)-mediated fusion and pseudotyped virus infection of HeLa cells but had no significant effect on infection of U87 cells.
This differential effect correlated with the detection of high-level surface expression of GLUT-1 on HeLa cells and very weak staining of U87
cells. To investigate this in terms of viral cytotropism, we cloned GLUT-1 cDNA from U87 cells and isolated two different versions of cDNA
clones: the wild-type sequence (encoding 492 residues) and a mutant cDNA with a 5-base pair deletion (GLUT-1Δ5) between nucleotides 1329
and 1333. The deletion, also detected in genomic DNA, resulted in a frame-shift and premature termination producing a truncated protein of 463
residues. Transfection of the wild-type GLUT-1 but not GLUT-1Δ5 cDNA into CHO cells resulted in efficient surface expression of the human
GLUT-1. Co-expression of GLUT-1 with GLUT-1Δ5 produces a trans-inhibition by GLUT-1Δ5 of GLUT-1-mediated HTLV-1 envelope (Env)-
mediated fusion. Co-immunoprecipitation experiments demonstrated physical interaction of the wild-type and mutant proteins. Northern blot and
RT-PCR analyses demonstrated lower GLUT-1 RNA expression in U87 cells. We propose two mechanisms to account for the impaired cell
surface expression of GLUT-1 on U87 cells: low GLUT-1 RNA expression and the formation of GLUT-1/GLUT-1Δ5 heterodimers that are
retained intracellularly. Significant RNAi-mediated reduction of endogenous GLUT-1 expression impaired HTLV-1 Env-mediated fusion with
HeLa cells but not with U87 cells. We propose a GLUT-1-independent mechanism of HTLV-1 infection of U87 cells. The results may have
important implications for HTLV-1 neurotropism and pathogenesis.
© 2006 Elsevier Inc. All rights reserved.Keywords: Virus entry; HTLV-1; Neurotropism; GLUT-1 mutationsAbbreviations: Env, envelope glycoprotein; Env63, wild-type HTLV-1
envelope glycoprotein; Unc63, a cleavage mutant of HTLV-1 Env63 defective in
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Human T-cell leukemia virus type 1 (HTLV-1), the first
discovered disease-causing human retrovirus isolate, is the
etiologic agent of adult T-cell leukemia/lymphoma (ATLL) and
a progressive demyelinating disease known as tropical spastic
paraparesis/HTLV-1-associated myelopathy (reviewed in Feuer
and Green, 2005; Gallo, 2005; Yoshida, 2005). HTLV-1 is
endemic in Southern Japan, West Africa, Central and South
America, and the Caribbean basin (reviewed in Feuer and
Green, 2005). Although HTLV-1 was the first human retrovirus
to be isolated and characterized, its study has been hampered by
poor viral infectivity as manifested by low cell-free and cell-
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glucose transporter type 1 (GLUT-1) as a receptor for HTLV-1
and HTLV-2 (Manel et al., 2003). Coskun and Sutton confirmed
that GLUT-1 expression in the relatively resistant MDBK cells
resulted in enhancement of syncytia formation and HTLV-1
infection (Coskun and Sutton, 2005).
GLUT-1 protein belongs to the family of glucose
transporter proteins that have twelve membrane-spanning
domains, seven intracellular domains and six extracellular
domains (reviewed in Mueckler, 1994). The first extracellular
domain (ECL1) is the largest, with a predicted 33 amino
acids, and has a single N-linked glycosylation site. We have
recently demonstrated that antibodies to ECL1 inhibit HTLV-1
Env-mediated fusion and viral infection of CD4+ T
lymphocytes and suggested that the observed in vivo cytotrop-
ism may be due to the high GLUT-1 density on CD4+ T
lymphocytes (Jin et al., 2006). It remains unclear, however,
whether GLUT-1 is functioning as a receptor, a coreceptor, or as
an attachment cofactor. A recent report that added further
controversy demonstrated that heparan sulfate proteoglycan
(HSPG) is as a receptor for HTLV-1 on primary CD4+ T
lymphocytes (Jones et al., 2005). HSPG has been previously
shown to function as a non-specific attachment factor for many
viruses (reviewed in Manel et al., 2005). Manel et al. were the
first to suggest that, in addition to GLUT-1, other cofactors/
coreceptors might be involved in HTLV-1 infection (reviewed
in Manel et al., 2005). However, the lack of a cell system that
does not express GLUT-1 has made it difficult to provide
experimental evidence for the potential expression of alternative
receptors/coreceptors.
The literature reported a number of observations that favor
the cofactor/coreceptor model. First, it is still unclear whether
the in vivo tropism of HTLV-1 can be explained solely by
GLUT-1 expression since GLUT-1 is widely expressed.
Furthermore, the wide host range of HTLV-1 in vitro cannot
only be explained by GLUT-1 expression since a number a
studies observed different binding and infection efficiencies of
non-human cell lines (reviewed in Manel et al., 2005).
Additionally, there has been no evidence that HTLV-1 uses
GLUT-1 or other receptors to infect the different mammalian
cell lines. It has been assumed that infection of mammalian cell
lines is mediated by endogenous GLUT-1 based on Env binding
analysis (Jassal et al., 2001). In the present study, we describe
that U87 cells, which are highly susceptible to HTLV-1
infection, express very low levels of GLUT-1 protein on the
cell surface and that antibodies to GLUT-1 do not inhibit HTLV-
1 Env-mediated fusion and pseudotyped virus infection of U87
cells. Northern and RT-PCR analyses indicated low abundance
of GLUT-1 RNA in U87 cells compared to HeLa or 293 cells.
We identified a 5 bp deletion in the gene encoding the GLUT-1
protein that resulted in a frame-shift and a truncated GLUT-1
protein. We found that U87 cells are heterozygous for the
deleted GLUT-1 allele. We propose a GLUT-1-independent
mechanism for HTLV-1 infection of U87 cells. Since U87 cells
are an astrocytoma/glioblastoma cell line derived from a human
brain tumor, our results may have important implications for
HTLV-1 neurotropism.Results
U87 cells are highly permissive to HTLV-1
To determine the susceptibility of U87 cells to HTLV-1, we
examined these cells as targets in the Env-mediated fusion assay
andmeasured their ability to support pseudotyped virus infection.
We used HeLa cells as positive control since they are susceptible
to Env fusion and HTLV-1 infection. To control for non-specific
Env interactions, we used a mutant envelope protein Unc63 that
had its cleavage site at residues 309–312 (RSRR) mutated to
GLGL (Jin et al., 2006). We consistently observed higher Env-
mediated fusion (Fig. 1A) and infection signals (Fig. 1B) with
U87 cells. We also observed some degree of permissiveness with
the non-human cell lines CHO and MDBK; however, the fusion
and infectivity signals were significantly lower than observed
with U87 or HeLa cells (Figs. 1A and B). Consistent with recent
data in the literature (Coskun and Sutton, 2005),MDBK seems to
be the least susceptible to HTLV-1 Env fusion and viral infection.
The competence of all cell lines to undergo cell fusion and viral
infection was confirmed by VSV Env fusion (Fig. 1C) or VSV
infection (Fig. 1D). The results demonstrate that U87 cells are
highly susceptible to HTLV-1 Env fusion and pseudotyped virus
infection.
GLUT-1 surface expression on U87 cells does not correlate
with HTLV-1 Env fusion
To determine whether the high susceptibility of U87 cells to
HTLV-1 Env fusion is due to high expression levels of the
GLUT-1 receptor, we examined the effect of GLUT-IgY
antibodies on Env fusion. Pre-incubating these antibodies
with the target cells prior to mixing with Env-expressing cells
demonstrated efficient blocking of Env fusion with HeLa cells
but no effect on Env fusion observed with U87 cells (Fig. 2A).
The inhibitory effect was specific to HTLV-1 Env-mediated
fusion since VSV fusion was not significantly altered following
incubation with GLUT-IgY (Fig. 2A). Higher concentrations of
the antibody had no significant effect on Env fusion with U87
cells (data not shown). FACS analysis was performed to
compare surface levels of U87 GLUT-1 to that expressed in
HeLa cells. The antibodies used were chicken anti-human
GLUT-IgY raised against the first extracellular loop (ECL1) of
GLUT-1 (Jin et al., 2006). HeLa cells consistently expressed
high levels of cell surface GLUT-1, whereas U87 showed very
weak staining of this antigen over the pre-immune control (Fig.
2B). To determine whether this weak staining is not due to
antibody recognition, we transfected the U87 with a plasmid
DNA encoding wild-type GLUT-1 and analyzed expression by
FACS. The results show significant increase of cell surface
GLUT-1 on transfected cells (Fig. 2C). Western blot analysis of
GLUT-1-transfected cells demonstrated expression of the
recombinant GLUT-1 in U87 cells (Fig. 2C, right). The
observed broad protein band in U87 cells co-migrated with
that in HeLa cells indicating their source from the transfected
DNA (Fig. 2C). In contrast, western blot analysis of
endogenous GLUT-1 protein revealed the expression of a
Fig. 1. Efficient HTLV-1 Env fusion and pseudotyped virus infection of U87 cells. (A) HTLV-1 Env-mediated fusion. 293 cells were co-infected with vaccinia virus
encoding either Env63, Unc63, or VSV and pT7-lacZ reporter. The target cell lines indicated at the x axis were infected with vaccinia virus expressing T7 RNA
polymerase. Following overnight incubation at 31 °C, Env-expressing cells were mixed with the target cells and incubated for 2.5 h. The Env-mediated fusion was
assessed by measuring the amount of β-galactosidase produced in detergent-treated cell lysates. (B) Pseudotyped virus particles carrying Unc63, Env63, or VSV-G
were used to infect the indicated cell lines (0.3 × 106 cells/infection) in duplicates and incubated for 48 h at 37 °C. Cell lysates were prepared, and luciferase activity
was measured. The data are expressed as relative light units (RLU). C and D show Env fusion with VSV (C) and VSV infection (D) to confirm the competence of the
cells in Env fusion and infection assays.
101Q. Jin et al. / Virology 353 (2006) 99–110diffused and a faster migrating GLUT-1 protein band in U87
cells compared to HeLa cells (Fig. 2D). The protein band
representing GLUT-1 above the 50 kDa marker was signifi-
cantly lower in U87 cells compared to HeLa cells (Fig. 2D).
To compare GLUT-1 RNA expression in U87 cells with other
human cell lines, we performed northern blot analysis on total
RNA and used GLUT-1 cDNA as a probe. The results show
significant lower levels of GLUT-1 RNA in U87 cells compared
to HeLa and 293 cells (Fig. 2E). The lower levels of GLUT-1
RNA in U87 cells were confirmed by RT-PCR analysis using
purified total RNA as a template (Fig. 2F). To control for gel
loading, equivalent levels of β-actin RNA were detected in all
three human cell lines (Figs. 2E and F). Together, these results
show defects in GLUT-1 expression at the RNA as well as at the
post-translational levels in U87 cells. We propose a GLUT-1-
independent pathway for HTLV-1 infection of U87 cells.
HTLV-1 infection of U87 cells is sensitive to anti-gp46
antibodies but not to GLUT-IgY antibodies
To examine the effect of GLUT-IgY on HTLV-1 infection,
we compared the effect of pre-incubating these antibodies withHeLa or U87 cells prior to infection. The results show a dose-
dependent inhibition of HTLV-1 infection of HeLa cells (Fig.
3A) but no significant effect observed with U87 cells (Fig. 3B).
To show that infectivity signal obtained with U87 is mediated
by HTLV-1, we examined the effect of human monoclonal
antibodies (HMAbs) PRH-11A (obtained from Dr. Steven
Foung, Stanford University) that have been previously shown to
inhibit HTLV-1 infection (Hadlock et al., 1997). The results
show efficient blocking of HTLV-1 infection of HeLa (Fig. 3C)
as well as U87 cells (Fig. 3D). These results suggest a GLUT-1-
independent pathway for the efficient infection of U87 cells.
Cloning of GLUT-1 DNA from HeLa and U87 cells
Since transfection of GLUT-1 cDNA into U87 cells restores
surface expression of the protein (Fig. 2), it was logical to
analyze the DNA sequence of the gene for potential mutations.
We cloned and isolated the cDNA encoding the GLUT-1 cDNA
from U87 and HeLa cells. Sequence comparison of the cloned
GLUT-1 cDNAwith the human erythrocyte/HepG2 transporter
gene (GenBank NM006516) indicated a T to C transition at
nucleotide 454 in exon 4, which resulted in the substitution of
Fig. 2. HTLV-1 Env-mediated fusion is sensitive to GLUT-IgY. (A) The indicated cells were infected with vaccinia vector encoding pT7-lacZ, pre-incubated with
either pre-immune or GLUT-IgY for 45 min at 37 °C then mixed with the indicated Env-expressing 293 cells. The effect of GLUT-IgYantibodies was measured by the
amount of β-galactosidase produced. (B) The target cells in Awere analyzed by FACS using GLUT-IgY as the primary antibody and an FITC-conjugated secondary
antibody as described in Materials and methods. (C) The indicated cells were transfected with a plasmid DNA encoding GLUT-1 under vaccinia promoter, and protein
expression was activated by infection with recombinant vaccinia virus vTF7-3. The cells were then analyzed by FACS and western blotting as described in Materials
and methods. The number at the right side of the protein blot represents the position of the 50 kDa molecular weight marker. (D) Western blot analysis of GLUT-1
expression in the infected cell lines used in U87 and HeLa cells. For western blotting, antibodies specific to the carboxy-terminus of GLUT-1 were used to probe
protein expression. (E) Northern blot analysis of GLUT-1 RNA expression in the indicated cell lines. Equivalent amounts (25 μg/lane) of cytoplasmic RNA were
loaded on a 1% agarose containing 0.6 M formaldehyde and blotted. The blot was probed with 32-P-labeled GLUT-1 cDNA fragment as described in Materials and
methods. The blot was stripped and reprobed with β-actin cDNA. (F) RT-PCR analysis of GLUT-1 RNA expression in the indicated cell lines. The procedure is
detailed in the Materials and methods section. The primers amplify a fragment of ∼1.6 kb that represents the entire human GLUT-1 cDNA. The same amounts of
cytoplasmic RNA were used to amplify the endogenous β-actin RNA.
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on GLUT-1 receptor activity (data not shown). The same
mutation was also identified in some cDNA clones isolated
from U87 cells. Two out of ten U87 GLUT-1 cDNA clones had
a five base pair (GTTCT) deletion between nucleotide 1507 and
1511 in exon 10 (Fig. 4A). This deletion caused a frame-shift
and premature termination at codon 451, resulting in a truncated
protein missing the last 29 amino acids of the wild-type GLUT-
1 protein (Fig. 4A).
To determine whether the 5 bp deletion is present in the
genomic DNA, we used genomic DNA isolated from U87 cells
and HeLa cells as templates to amplify the region spanning the
deletion. The PCR products were cloned into pGEM-T easy
vector and analyzed by direct DNA sequencing. The results
indicated the presence of the 5 bp deletion in two of the six
genomic clones sequenced. These results confirm that U87 is aheterozygous for this 5 bp deletion. To confirm this genotype,
we compared the PCR products from exon 10 amplified from
HeLa and U87 genomic DNA. The results demonstrate the
presence of one band in HeLa cells but two bands in U87 cells
confirming the heterozygosity of U87 cells (Fig. 4B). To verify
expression of the GLUT-1Δ5 mutant protein, we transfected
CHO cells with plasmid DNA encoding either wild-type GLUT-
1 or GLUT-1Δ5 proteins. The protein expression was analyzed
by western blotting using antibodies to the C-terminus of
GLUT-1 (Fig. 4C) or to the His-tag introduced at the C-termini
of the proteins (Fig. 4D). As expected, antibodies to the C-
terminus detected the wild-type GLUT-1 but not the GLUT-1Δ5
mutant protein (Fig. 4C). However, His-tag antibodies detected
both the His-tagged wild-type GLUT-1 and the mutant GLUT-
1Δ5 proteins (Fig. 4D). The sizes of the his-tagged proteins
were comparable to those endogenously expressed in U87 and
Fig. 3. Inhibition of HTLV-1 infection of HeLa but not U87 cells by GLUT-IgY. The indicated concentrations of antibodies were pre-incubated for 30 min at 37 °C with
HeLa (A and B) or U87 cells (C and D) then infected (0.3 × 106 cells/infection) in duplicates with pseudotyped viral particles carrying either Unc63 control or Env63.
Following incubation at 37 °C for 48 h, the cell lysates were prepared and luciferase activity measured.
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open reading frame encoded by the cloned GLUT-1Δ5 cDNA.
Trans-dominant negative effect of GLUT-1Δ5 on wild-type
GLUT-1
To explain the significantly reduced levels of GLUT-1 in
U87 cells and analyze the effect of the deleted allele on GLUT-1
expression, we constructed recombinant vaccinia viruses
encoding either wild-type GLUT-1 or the GLUT-1Δ5 mutant
protein. The viruses were used to infect CHO cells either
individually or in combination as indicated in Fig. 5 and Table
1. CHO cells were infected with the recombinant viruses and
divided into three parts: the first used as targets in the Env
fusion assay (Fig. 5A), the second used for western blotting
(Figs. 5B, C, and D), and the third used for FACS analysis
(Table 1). The results demonstrated that CHO cells expressing
vaccinia-encoded GLUT-1 exhibited a high Env fusion signal
and co-expression of vaccinia-encoded GLUT-1Δ5 significant-
ly reduced that signal (Fig. 5A). The reduction of the fusion
signal was specific to HTLV-1 Env since VSV fusion was not
affected by expression of GLUT-1Δ5 (VSV fusion data cited at
the end of Fig. 5 legend). Interestingly, expression of the
truncated mutant GLUT-1Δ5 proteins down-modulated the lowEnv fusion observed with CHO cells (Fig. 5A; 0, 5, 5 and 0, 10,
0 lanes). Expression of the recombinant proteins was confirmed
by western blotting as shown in Figs. 5B, C, and D. To explain
the reduced Env fusion by GLUT-1Δ5 expression in Fig. 5A,
the same infected cell samples were analyzed for cell surface
GLUT-1. FACS analysis indicated that expression of GLUT-
1Δ5 protein caused a significant down-modulation of cell
surface GLUT-1 (Table 1). The results suggest that GLUT-1Δ5
protein exerts a trans-dominant negative effect on wild-type
GLUT-1.
Physical interaction of GLUT-1 and GLUT-1Δ5 proteins
To determine whether inability to detect surface GLUT-1Δ5
protein is not due to altered recognition by GLUT-IgY, we
performed FACS analysis on permeabilized CHO cells that
have been transfected with either wild-type GLUT-1 or GLUT-
1Δ5 plasmid DNA. The results demonstrate efficient staining of
GLUT-1Δ5 protein in transfected CHO cells upon permeabi-
lization of the cells (Fig. 6A). This confirms the ability of
GLUT-IgY to detect the mutant protein and suggests that
GLUT-1Δ5 protein is mainly intracellular.
To examine physical association of wild-type GLUT-1 and
mutant GLUT-1Δ5 (His-tag) proteins, we used CHO cells
Fig. 4. DNA and amino acid sequences of the deleted mutant allele of the GLUT-1 gene. (A) The last 40 residues of the carboxy-terminus of the wild-type GLUT-1 are
shown in letter code above the DNA sequence. The position of the 5-bp deletion is underlined and in bold, and the resulting frame-shift amino acids are shown
underneath the wild-type sequence (GLUT-1Δ5). The position of the inserted His-tag is shown. The boxed amino acids of the wild-type GLUT-1 represent the region
used to generate the commercial GLUT-1 antibodies (see Materials and methods). (B) Genotyping the GLUT-1 of HeLa and U87 cells. Genomic DNAwas used as
template to amplify a fragment that spans the 5-bp deletion (see Materials and methods). The products were analyzed in a 4% agarose gel. The arrows indicate the
position of the wild-type allele. Panels C and D show western blot analysis of the GLUT-1 proteins expressed in CHO cells transfected with DNA encoding vector
alone, wild-type GLUT-1, or mutant GLUT-1Δ5 proteins. The blots were probed with antibodies against GLUT-1 C-terminus (C) or against His-tag (D). GAPDH
probing of a similar blot was performed to verify gel loading.
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protein separately or co-express both proteins by co-infection
(wt + Δ5). We used a His-tagged GLUT-1Δ5 and a wild-type
GLUT-1 vector lacking the His-tag. The cellular lysates were
prepared and immunoprecipitated (IP) with antibodies to the C-
terminus of GLUT-1 (anti-COOH). These antibodies do not
react with the GLUT-1Δ5 protein since the truncated protein
lost the amino acids to which these antibodies were raised. The
IP samples were fractionated in SDS-PAGE and immuno-
blotted. Probing the immunoblot with anti-His antibodies
detected the His-tagged GLUT-1Δ5 protein in cells co-
expressing both wild-type and mutant (Fig. 6B, anti-His). The
only way to detect this protein band is if the protein had been
complexed with the wild-type GLUT-1 during the IP procedure.
The blot was stripped and reprobed with the same antibodies
used in IP. As expected, the C-terminal antibodies detected the
wild-type GLUT-1 protein bands but not the His-tagged mutant
GLUT-1Δ5 (Fig. 6B, anti-COOH). Stripping and reprobing
with the rabbit normal serum did not reveal any specific protein
bands (Fig. 6B, right panel). To verify the accuracy of gel
loading, we subjected the blot to a final stripping and reprobing
with anti-GAPDH.
To confirm these results, we performed the IP experiment
using the anti-His antibodies, analyzed samples on SDS-PAGE
and immunoblotting. Probing the blot with anti-COOH
antibodies detected the wild-type GLUT-1 protein in cells co-
expressing both proteins (Fig. 6C, anti-COOH). Probing the
same blot (after stripping) with anti-His detected the his-tagged
GLUT-1Δ5 proteins in cells co-expressing both proteins or in
cells expressing GLUT-1Δ5 alone (Fig. 6C, anti-His Blot). As anegative control, stripping and reprobing this blot with NRS did
not reveal any specific protein bands (Fig. 6C, right panel).
GAPDH antibodies verified equivalent gel loading of all
samples. The results suggest physical interaction of wild-type
GLUT-1 with GLUT-1Δ5 proteins as a mechanism to explain
the impaired surface expression of GLUT-1 in U87 cells.
siRNA-mediated reduction of GLUT-1 protein expression
results in blocking HTLV-1 Env-mediated fusion with HeLa
cells but not with U87 cells
To further examine the role of GLUT-1 protein expression in
mediating HTLV-1 Env fusion in HeLa and U87 cell lines, we
utilized siRNA to directly reduce GLUT-1 protein expression in
cultured cells. Three different siRNA molecules were designed
against different regions of GLUT-1 mRNA. The siRNA
designed against the open reading frame (ORF) of GLUT-1
gave the best results in terms of reducing GLUT-1 protein
expression. FACS analysis (data not shown) and western blot
analysis (Fig. 7A) confirmed the significant reduction of GLUT-
1 protein expression following siRNA transfection. The ORF
siRNA caused ∼75% reduction in GLUT-1 protein expression
as measured by western blotting (Fig. 7A). As a negative
control, we transfected siRNA molecules not related to GLUT-1
(Control siRNA) into the cell lines and considered that as the
reference level of endogenous GLUT-1 expression. The effect
of reducing GLUT-1 expression on HTLV-1 Env-mediated
fusion was examined using siRNA-transfected cells as targets.
Efficient inhibition (∼75%) of Env-mediated fusion with HeLa
cells was consistently observed in every experiment performed.
Fig. 5. Trans-dominant inhibition of GLUT-1-mediated HTLV-1 Env fusion by
GLUT-1Δ5. (A) CHO cells were infected with the indicated recombinant
vaccinia viruses encoding wild-type GLUT-1, mutant GLUT-1Δ5, or combi-
nation of both at the indicated infectivity (pfu/cell). WR is the vaccinia vector
that does not encode any GLUT-1-related sequence and is used to control for
virus input. The cells were co-infected with a vaccinia virus encoding T7 RNA
polymerase. Following overnight incubation to allow expression of recombinant
proteins, each infected cell sample was divided into three parts: one part was
used for FACS analysis to measure GLUT-1 surface staining (Table 1) and
another used for western blotting to verify expression of the recombinant
proteins (B–D). The third part was used in Env fusion assay where the cells were
mixed with 293 cells expressing either Unc63, Env63, or VSV and pT7-LacZ
and incubated for 2.5 h to allow cell fusion. The extent of cell fusion was
assessed by measuring β-galactosidase in detergent-treated cell lysates (A). The
VSV fusion values in this experiment were recorded from left to right: 130, 129,
125, 128, 123, and 127.
Table 1











10 0 0 5.0 155.8
5 0 5 6.0 125.6
5 5 0 5.5 60.8
0 5 5 5.2 14.6
0 10 0 5.1 8.9
0 0 10 4.9 20.8
MIF, mean fluorescence intensity. WR is a vaccinia virus vector that does not
encode GLUT-related proteins or any other foreign protein. WR is used to
control for the virus input.
a Flow cytometric analysis of cell surface GLUT-1 protein on CHO after
infection with recombinant vaccinia viruses encoding the indicated proteins.
PFU, plaque forming units, refers to the virus input. MIF, mean fluorescence
intensity. WR is a vaccinia virus vector that does not encode GLUT-related
proteins or any other foreign protein. WR is used to control for the virus input.
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mediated fusion with U87 cells (Fig. 7B). The competence of
cells to undergo cell fusion was verified by VSV Env fusion
(Fig. 7C). These results suggest a GLUT-1-independent
pathway for HTLV-1 Env-mediated cell fusion in U87 cells
and implicate the usage of another unknown receptor on this
glioblastoma/astrocytoma cell line.
Discussion
This study reports a genetic mutation in the GLUT-1 gene in
the glioblastoma/astrocytoma U87 cell line. We identified a 5 bp
deletion in exon 10 that resulted in a frame-shift of the GLUT-1
protein at residue 443 and a premature termination at residue
451. The truncated mutant protein contained 8 frame-shift
amino acids not present in wild-type sequence and had a
negative trans-dominant effect on the cell surface expression of
the GLUT-1 protein in U87 cells. The heterozygosity of the U87
cell line has been confirmed by the genomic DNA analysis. It
may be argued that the U87 cells we used might be aheterogeneous population of cells, one homozygous for the
wild-type GLUT-1 allele and the other homozygous for the
deleted allele. This is unlikely since we performed multiple
rounds of cell cloning to obtain a pure population. Furthermore,
GLUT-1 gene knock-out (−/−) cells were determined to be
nonviable (Heilig et al., 2003).
The impaired cell surface expression of GLUT-1 protein is a
significant finding in terms of HTLV-1 neurotropism since it
implicates a GLUT-1-independent pathway for the observed
efficient HTLV-1 infection of these cells. The U87 cell line may
serve as an ideal candidate to investigate the mechanism of
HTLV-1 neurotropism. Different mutations or deletions in
different positions in the open reading frame of human GLUT-1
gene have been previously identified in patients with GLUT-1
deficiency syndrome (Wang et al., 2005). The syndrome is
characterized by impaired glucose transport across the blood–
brain barrier, infantile seizures, developmental delay, acquired
microcephaly, spasticity, ataxia, and hypoglycorrhachia (Wang
et al., 2005). Since U87 cells were derived from a human brain
tumor, we propose that HTLV-1 infection of the brain might be
mediated by a receptor that is specific to the brain tissue.
Several lines of experimental evidence suggest a GLUT-1-
independent entry of HTLV-1 into U87 cells. First, antibodies
that block HTLV-1 Env-mediated fusion and virus infection of
HeLa cells had no effect on Env-mediated fusion or viral
infection of U87 cells. Second, northern blot and FACS
analyses indicated that U87 cells express low GLUT-1 RNA
and very low levels of GLUT-1 protein at the cell surface. The
GLUT-1 protein density on U87 does not correlate with the very
efficient Env fusion and HTLV-1 infection rates. Third, the
identification of a genomic deletion in the U87 GLUT-1 gene
provides a genetic explanation for the impaired surface
expression of GLUT-1. The low surface levels of GLUT-1 on
U87 cells are not due to a detection problem since surface
expression could be rescued by transfecting with wild-type
GLUT-1. Finally, siRNA-mediated reduction of endogenous
GLUT-1 protein expression impaired HTLV-1 Env-mediated
fusion with HeLa cells but had no significant effect on fusion
with U87 cells.
Fig. 6. Detection of intracellular GLUT-1Δ5 protein. (A) CHO cells were transfected with plasmid DNA encoding the indicated His-tagged proteins under vaccinia
early/late promoter. Expression of the protein was activated by infection with vaccinia virus WR. The cells were divided into two aliquots, one was directly incubated
with GLUT-IgY (Non-permeabilized); the other was treated with 0.3% Triton X-100 for 20 min at 4 °C then incubated with GLUT-IgY (Permeabilized). (B and C)
Heterodimerization of GLUT-1 and GLUT-1Δ5 proteins. CHO cells were infected with vGLUT-1 (wt), vGLUT-1Δ5 (Δ5), or co-infected by both recombinant viruses
(wt +Δ5) at 10 pfu/cell for each virus. Total cellular lysates were prepared and immunoprecipitated (IP) with antibodies to the carboxy-terminus of GLUT-1 (detect wt
only). The immunoprecipitated samples were fractionated in 10% SDS-PAGE and transferred into PVDF membranes. The blots were first probed with anti-His
antibodies (detect the His-tagged GLUT-1Δ5 mutant protein) (B, left panel). The blot was then sequentially stripped and reprobed with antibodies to the C-terminus of
Wt GLUT-1 (B, middle panel) then normal rabbit serum (NRS). A final stripping and reprobing with GAPDH were performed to show appropriate gel loading.
Another sample of cellular lysates was IP with Anti-His, blotted and probed with antibodies to the C-terminus (C, middle panel), stripped and reprobed with anti-His-
tag (C, right panel), then stripped and reprobed with NRS (C, left panel). A final stripping and reprobing with GAPDHwere performed to show appropriate gel loading.
The anti-His antibodies used in these experiments were rabbit polyclonal purchased from Santa Cruz Biotechnology, Santa Cruz, California.
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its size was significantly different from that expressed in HeLa
cells. The smaller size of GLUT-1 in U87 can be explained by
the smaller size of the protein encoded by the deleted allele. InFig. 7. GLUT-1 is not required for HTLV-1 Env fusion with U87 cells. HeLa cells or
siRNA or irrelevant control siRNA. GLUT-1 expression was verified by western blott
control siRNA (Lane 1) or with 10 nM (Lane 2) or 100 nM (Lane 3) of GLUT-1 siR
polymerase and mixed with 293 cells expressing either Unc63 or Env63 and the repor
by measuring the amount of β-galactosidase produced as a result of Env-mediated ce
confirmed by VSV Env-mediated fusion (C). The numbers at the left side of each blo
lanes in A correspond to the same numbers indicated in panel B and C.addition to the truncated GLUT-1Δ5 protein, U87 cells also
express the wild-type GLUT-1 protein. It is possible that U87
cells express different forms of wild-type GLUT-1 protein
and that different glycosylation and processing could haveU87 cells were transfected with the indicated concentrations of GLUT-1-specific
ing (A). Lanes 1, 2, and 3 refer to cells that are either transfected with the 100 nM
NA. The transfected cells were infected with a vaccinia virus encoding T7 RNA
ter T7-lacZ. The effect of siRNA inactivation of GLUT-1 expression was assayed
ll fusion. The competence of siRNA-transfected cells to undergo cell fusion was
t indicate the positions of the protein marker bands (Kd). The numbers above the
107Q. Jin et al. / Virology 353 (2006) 99–110contributed to the inability of antibodies to interact with surface
GLUT-1. This seems unlikely since transfection of U87 with the
wild-type GLUT-1 cDNA results in enhancement of cell surface
expression of GLUT-1. The fact that GLUT-IgY antibodies that
poorly stain U87 cells efficiently detect the protein upon
permeabilization of the cells argues against impaired antibody
recognition (Fig. 6A). The U87 cell line is heterozygous for the
deleted mutant GLUT-1 allele, which results in a trans-
dominant negative effect on the wild-type GLUT-1 protein in
U87 cells. We found that GLUT-1Δ5 protein encoded by the
deleted allele physically interacts with the wild-type GLUT-1
and reduces its availability at the cell surface. This was evident
by the trans-dominant inhibition effect on HTLV-1 Env fusion
in CHO cells co-expressing recombinant GLUT-1Δ5 and the
wild-type GLUT-1 proteins.
Previous studies described a C-terminal truncated rabbit
GLUT-1 without transport activity (Oka et al., 1990). Oka et al.
proposed that the C-truncated protein is integrated into
membranes in a fashion similar to the wild-type protein;
however, it has a different conformation, with the inner glucose
binding site locked into an inward-facing form. The C-truncated
GLUT-1 described by Oka et al. is different from the truncated
GLUT-1Δ5 protein described in this study. Oka et al. deleted
the last 37 amino acids of the rabbit GLUT-1, and the mutant
protein does not contain frame-shift amino acids. The truncated
GLUT-1Δ5 protein lost 29 residues of the human GLUT-1 C-
terminus and had 8 frame-shift amino acids, a net loss of 21
amino acids at the C-terminus. Furthermore, the study by Oka et
al. did not analyze surface expression of the truncated protein,
and the conclusions made were based on the inability of their C-
truncated mutant protein to transport glucose (Oka et al., 1990).
The role of the new motif in GLUT-1Δ5 protein is not clear.
The potential new role of the 8 frame-shift amino acids could
probably be related to cell surface transport of GLUT-1. The
motif sequence HLHLLQSS may function as an intracellular
retention sequence. Deletion of this sequence may reveal its
potential role as a retention signal. Previous studies demon-
strated that a single intramolecular disulfide bond promotes
tetramerization of GLUT-1 (Zottola et al., 1995). Zottola et al.
demonstrated that the glucose transporter function is controlled
by GLUT-1 oligomeric structure and identified Cys347 and
Cys421 as the residues involved in the disulfide bridge that
stabilizes the structure and accelerates transporter function
(Zottola et al., 1995). Cys347 and Cys421 are intact in the
GLUT-1Δ5 truncated protein, and their presence may explain
the ability of the mutant protein to form heterodimers with wild-
type GLUT-1. However, it is possible that the loss of the last 21
residues may have affected the efficiency of tetramerization of
GLUT-1 and subsequently cell surface transport. We have
consistently observed faster gel mobility and a more diffused
protein band for the endogenous wild-type GLUT-1 protein
(encoded by the wild-type allele) in U87 cells. It is possible that
interaction of GLUT-1Δ5 protein with wild-type GLUT-1 in
U87 cells induces instability and degradation of the latter,
resulting in impaired cell surface transport. The diffused faster
migrating GLUT-1 protein band in U87 cells was detected with
antibodies raised to the last C-terminal residues of GLUT-1 thatare missing from GLUT-1Δ5 mutant protein. This indicates
expression of the wild-type GLUT-1 allele in U87 cells.
In conclusion, the results of this study implicate that another
unknown receptor is involved in HTLV-1 entry and infection of
U87 cells. The identification of this putative receptor(s) may
provide important insight into the mechanism of retroviral entry




HeLa cells, 293 cells, and CHO cells were obtained from the
American Type Culture Collection. U87 cells were obtained
from NIH AIDS Research and Reference Reagent Program (lot
# 4 021998). The U87 cells were subjected to multiple rounds of
cell cloning in the presence of 10% cosmic calf serum
supplemented with glial cell medium containing G-5 supple-
ment (GIBCO). Cells were grown in DMEM containing 10%
cosmic calf serum (U87 cells) or 10% fetal bovine serum (293,
HeLa and CHO), penicillin G (100 units/ml), and streptomycin
sulfate (0.1 mg/ml) in a humidified incubator held at 5% CO2.
All cell culture media were purchased from GIBCO.
The recombinant vaccinia viruses used in our Env-mediated
fusion assay have been previously described (Agrawal et al.,
2002, 2004a, 2004b). Recombinant vaccinia viruses encoding
either GLUT-1 or GLUT-1Δ5 under vaccinia early/late
promoter have been constructed by transfecting HeLa cells
with pSC59 plasmid encoding either protein and infection with
WR as previously described (Broder and Earl, 1997). Briefly,
plaques were isolated after transfection/infection and screened
by dot blotting with a probe corresponding to GLUT-1
sequences. The positive plaques were subjected to three cycles
of plaque purification, and the final positive plaques were used
to generate virus stocks on HeLa cells.
HTLV-1 Envy-mediated fusion
Env-mediated cell fusion was determined by a vaccine-based
reporter gene assay (Jin et al., 2006). The assay analyzes fusion
between two distinct cell populations, one that expresses the
potential receptor along with the lacZ gene linked to the T7
promoter and another that expresses HTLV-1 Env and T7 RNA
polymerase encoded by a recombinant vaccinia virus. All cell
populations were incubated overnight at 31 °C to allow
expression of the vaccinia-encoded proteins. Duplicate samples
containing 105 target cells and same number of effector cells
were mixed in 96-well microtiter plates and incubated at 37 °C
for 2.5 h. The extent of Envy-mediated fusion was assayed by
colorimetric measurement of β-glycosidase activity in deter-
gent-treated cell lysates.
For blocking experiments, we used our IgY-GLUTantibodies
at increasing concentrations added to the target cells (105 HeLa
or U87 cells). For Env blocking, increasing concentrations of
human monoclonal antibodies to HTLV-1 Env were mixed with
105 Env-expressing cells in duplicate wells of 96-well tissue
108 Q. Jin et al. / Virology 353 (2006) 99–110culture plates. Control wells incubated with pre-immune serum
or isotype match antibodies were included. The antibodies were
incubated for 30 min at 37 °C and then mixed with the
corresponding cell population 105 and incubated at 37 °C for
2.5 h. The extent of cell fusion was quantified by a colorimetric
measurement of β-glycosidase produced using detergent–lysed
cell mixtures.
Pseudotyped virus infection
We adapted the improved pseudotyping assay developed by
Sutton and Littman (1996) to prepare pseudotyped virus
particles that carry the HTLV-1 Env protein. 293T cells were
cotransfected with 10 μg of PcREV and 10 μg of the
envelope-defective luciferase-transducing HIV proviral clone
pNL4-3.Luc+env− (He et al., 1995) (Catalog # 3418, AIDS
Reagent Program, NIH) in the presence or absence of 10 μg of
pHTLV−env−rre− using standard calcium phosphate. Fifteen
hours following transfection, 20 mM sodium butyrate and
fresh media were added. The supernatants were harvested after
48–72 h by low-speed centrifugation and filtrated through a
22 μm filter. Pseudotyped vesicular stomatitis virus G
glycoprotein (VSV-G) was used as a positive control to verify
the competence of cells in cell fusion.
HTLV-1 infection assays were performed by incubating
3 × 105 cells/ml containing 5 μg/ml polybrene mixed with 1 ml
of pseudotyped HTLV-1 virus stock and plated into the wells of a
six-well plate. The mixture was incubated for 4–5 h at 37 °C in a
5% CO2 incubator. Following incubation, the cells were washed
with 10% FBS and fresh medium added and incubation
continued for another 48 h. The cells were harvested, and
luciferase assay was performed using the luciferase assay system
as recommended by the manufacturer (Promega, Madison, WI).
Cell surface expression of GLUT-1 and protein analysis
To detect GLUT-1 at the cell surface, we used a previously
described chicken polyclonal antibodies against a synthetic
peptide corresponding to the large extracellular domain of
GLUT-1 (ECL1) (Jin et al., 2006). We will refer to these
antibodies as GLUT-IgY to indicate the source of this antiserum.
Cells transfected with wild-type GLUT-1 or GLUT-1Δ5
mutant were washed with cold PBS containing 0.1% PBS/BSA,
pelleted by centrifugation for 8 min at 500 × g at 4 °C. After
fixing with 4% formaldehyde, the cells either permeabilized
(0.1% Triton X-100 for 15 min on ice) or unpermeabilized were
resuspended in 100 μl of 1% PBS/BSA containing 1:1000
dilution chicken anti-human GLUT-IgYantibody and incubated
on ice for 30 min. The cells were washed with 1% PBS/BSA,
pelleted, and resuspended in 100 μl of 1% PBS/BSA containing
2 μg of FITC-conjugated rabbit anti-chicken IgY (Biomeda,
Foster City, CA). The cells were then incubated on ice for
30 min, washed three times with 1% PBS/BSA solution,
resuspended in 1 ml of PBS, and analyzed in a FACS Vantage
flow cytometer (Becton-Dickinson, San Jose, CA).
Immunoblot analysis was performed using rabbit anti-
bodies raised against the C-terminal domain of GLUT-1(Dakocytomation, Carpinteria, CA). Cells were rinsed with
PBS, scraped on ice in PBS, and centrifuged at 500 × g.
Cell pellet was resuspended in protein lysis buffer
(300 mM NaCl, 50 mM Tris–HCL pH 7.6, 0.1% SDS,
Aprotonin 10 μg/ml, PMSF 1 mM) and incubated for
30 min on ice then sonicated for 1 min to shear the
genomic DNA. After centrifugation, the supernatants were
mixed with the same volume of protein loading buffer and
fractionated in a 12% SDS-PAGE (0.1 × 106 cells/lane) and
transferred into PVDF membrane blots. Blots were
incubated with rabbit antibodies directed against C-terminal
domain (1:2000) and left rocking overnight at 4 °C. The
blots were developed by BM Chemiluminescence using
peroxidase-conjugated antibody against mouse/rabbit IgG
(Roche, Indianapolis, IN).
For cell membrane preparations, cells were homogenized in
10 mM Tris, 1 mM EDTA, 1 mM phenylmethylsulfonyl
fluoride (PMSF), and 250 mM sucrose, pH 7.4, in Potter–
Elvehjem glass-Teflon type homogenizer at 4 °C. The
homogenates were centrifuged at 900 × g for 10 min to
sediment the fraction containing nuclei, and the supernatants
were centrifuged at 17,000 × g for 75 min at 4 °C. The pellets
were subjected to 12% SDS-PAGE. An equivalent of
0.1 × 106 cells was loaded per lane.
Northern blotting
Total cytoplasmic RNA was isolated from HeLa, U87, and
293 cells by using RNeasy Mini Kit purchased from QIAGEN,
Valencia, CA. Equivalent amounts of RNA (25 μg/lane) were
loaded on a 1% agarose gel containing 0.6 M formaldehyde.
The gel was transferred onto Zeta-Probe blotting membrane
(Bio-Rad, Hercules, CA) by blotting then cross-linking. The
blot was probed using a 32-P-labeled GLUT-1 cDNA fragment.
This GLUT-1-specific fragment was gel-purified after digestion
with NcoI.
RT-PCR cloning of GLUT-1 cDNA from U87 and HeLa cells
Total RNAwas isolated from U87 cells using TRIzol reagent
(Invitrogen Life Technologies, CA), according to the manufac-
turer's recommendation. Approximately, 5 μg of total RNAwas
used for reverse transcription with oligo (dT) as a reverse primer
(SuperScript First-Strand Synthesis System for RT-PCR,
Invitrogen Life Technologies). Five percent of the cDNA
product was used for PCR (Platinum Pfx DNA Polymerase,
Invitrogen Life Technologies) amplification of GLUT-1. The
PCR conditions were as follows: incubation for 5 min at 94 °C
followed by 30 cycles of 30 s at 94 °C, 30 s at 55 °C, and 2 min
at 68 °C, and a final extension for 7 min at 68 °C in a
PerkinElmer 9700 Thermal Cycler. The primers used to amplify
GLUT-1 from HeLa and U87 cells were: forward primer 5′-
CCACCAGCGCAGCGCTGCCA-3′ and reverse primer 5′-
CGAGTGGTGATCCTGGGGCGACTCA-3′. PCR products
were purified from 1% agarose gel stained with ethidium
bromide and ligated with pGEM-T Easy vector (Promega,
Madison, WI) after A-tailing procedure. The His-tagged wild-
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forward primer and the reverse primer: 5′-GGCTCGAGT-
CAATGGTGATGGTGATGATGCACTTGGGAAT-
CAGCCCC-3′. To construct a His-tagged GLUT-1 cloned
from U87 cells, we used the same forward primer as
described above and the following reverse His-tagged
primer: 5′-GGCTCGAGTCAATGGTGATGGTGATGATGG-
GAACTTTGAAGTAGGTG-3′. The purified fragments
corresponding to the encoded GLUT-1 were cloned into
pSC59 vector (described in Alkhatib et al., 1996) under the
control of vaccinia early/late promoter. The DNA sequence
of cloned DNA was verified by direct sequencing. The
plasmid DNA containing GLUT-1 from either HeLa or U87
cells was transfected into CHO cells by DOTAP Liposomal
Transfection Reagent (Roche, Indianapolis, IN). Expression
of GLUT-1 was activated by infection with vaccinia virus.
Cloning of genomic DNA fragments of GLUT-1 gene
Genomic DNAwas isolated from U87 and HeLa cells using
DNeasy Tissue Kit (QIAGEN, CA), according to the manufac-
turer's recommendation. The concentration and purity of
genomic DNA samples were measured, and 1 μg of genomic
DNA was used for PCR. For GLUT-1 cloned from HeLa and
U87 cells, the forward primer (nucleotides 1292–1312) used is:
5′-CTACGTTCTTCATCATCTTCACT-3′ and the reverse-
primer (nucleotides 1578–1598) used: 5′-GGAGCCCC-
AGGCCCGGCTCGG-3′. PCR products were ligated with
pGEM-T Easy vector, and positive clones were verified by
direct DNA sequencing.
siRNA experiments
The sequence of the synthetic siRNA complementary to the
GLUT-1 open reading frame is 5′-GGGCCAAGAGUGUG-
CUAAAGAAGC-3′ and complementary to the 3′UTR is 5′-
GGCUGGACCUAUGUCCUAAGGACACAC-3′ (Integrated
DNA Technologies, Coralville, IA). These siRNA molecules
were transfected together into HeLa or U87 cells using an
oligofectamine reagent purchased from Invitrogen (Invitrogen,
San Diego, CA). HeLa or U87 cells were plated at
1.5 × 105 cells/well in a 6-well plate using serum-free medium
without antibiotics. The siRNA (10 or 100 nM) was gently
mixed with the oligofectamine reagent and incubated for 20 min
then added to the corresponding well. After 4-h incubation at
37 °C, 0.5 ml of 3× serum was added. Following incubation for
72 h in a 37 °C incubator, the transfected cells were washed and
infected with pT7-lacZ reporter. Separate populations of 293
cells were infected with vaccinia viruses encoding either Unc63
or Env63 and T7 RNA polymerase. At 15 h post-infection, the
Env-expressing cells were mixed (1:1) with the siRNA-
transfected cells and incubated for 2.5 h to allow cell fusion.
The effect of siRNA on Env-mediated fusion was assayed by
measuring β-galactosidase produced. The control siRNA used
as a negative control was a scrambled sequence 5′-CUUCCU-
CUCUUUCUCUCCCUUGUGA-3′ purchased from Integrated
DNA Technologies, Coralville, IA.Acknowledgments
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